Comparative NAD-Boosting Efficacy of BluNADBooster (LN22199), Nicotinamide Riboside, and Their Combination in Healthy Aging Adults: Clinical Findings

Objectives

To determine the effects of BluNADBooster (LN22199), NR, or their combination on blood NAD+ levels, CD38 activity, inflammatory markers, cognitive function, physical performance, and quality of life in healthy aging adults.

Journal

Journal of Functional Foods

Key Outcomes

• LN22199 increased NAD+ levels by more than 26%, while NR boosted NAD+ by 23%. The combination of LN22199 and NR resulted in the greatest increase, with a 32% rise in NAD+ after 60 days, highlighting the synergistic effect of the two treatments.
• LN22199 uniquely reduced CD38 activity by nearly 18%. In contrast, NR had no significant impact on CD38 levels, suggesting that LN22199 helps protect NAD+ by reducing its enzymatic degradation, in addition to promoting its production.
• Both LN22199 and NR, especially when combined, led to significant reductions in inflammatory biomarkers.
• Both LN22199 and NR, individually and together, improved cognitive function and physical performance, with the combination showing the most significant gains in both areas.
• Improvements in health-related quality of life were seen with both LN22199 and NR, either alone or in combination. The combination treatment produced the most significant benefits, including enhanced physical functioning, energy levels, and pain management.

Duration

60 days

Dose

NR: 500 mg

LN22199: 500 or 1000 mg

Study Design

Randomized, double-blind, placebo-controlled, four-arm parallel assignment study in 140 healthy adults